What Influences Business Growth: Complementary Research on Synageva BioPharma, Array BioPharma, Sarepta Therapeutics, Fate Therapeutics and Dyax
NEW YORK, May 11, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Synageva BioPharma Corp. (NASDAQ: GEVA), Array BioPharma Inc. (NASDAQ: ARRY), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Fate Therapeutics Inc. (NASDAQ: FATE), and Dyax Corp. (NASDAQ: DYAX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
GEVA Research Report: ( http://get.analystsreview.com/pdf/?c=Synageva%20BioPharma&d=11-May-2015&s=GEVA ),
ARRY Research Report: ( http://get.analystsreview.com/pdf/?c=Array%20BioPharma&d=11-May-2015&s=ARRY ),
SRPT Research Report: ( http://get.analystsreview.com/pdf/?c=Sarepta%20Therapeutics&d=11-May-2015&s=SRPT ),
FATE Research Report: ( http://get.analystsreview.com/pdf/?c=Fate%20Therapeutics&d=11-May-2015&s=FATE ),
DYAX Research Report: ( http://get.analystsreview.com/pdf/?c=Dyax%20Corp.&d=11-May-2015&s=DYAX ).
============
--
Analyst Update: Acquisition, Strategic Partnership, and Earnings
U.S. stocks advanced sharply on Friday, after stronger employment data for April suggested the US economy is gaining traction again. The Dow Jones Industrial Average rose 1.49%, to close at 18,191.11, the S&P 500 gained 1.35%, to 2,116.10, and the NASDAQ Composite finished the session at 5,003.55, up 1.17%. European stocks rallied on Friday, lifted by the UK election results, which showed the Conservative Party unexpectedly sweeping into power again. Germany's DAX 30 rose 2.65%, France's CAC 40 advanced 2.48%, and the London's FTSE 100 closed 2.32% higher on Friday. Meanwhile, Asian markets surged on Friday after losing ground in the last few days. The Shanghai Composite, Japan's Nikkei, and Hong Kong's Hang Seng all posted gains on Friday.
Synageva BioPharma Corp. (Synageva) announced on May 6, 2015 that it has entered into a definitive agreement with Alexion Pharmaceuticals Inc. (Alexion) to be acquired by the latter. Under the terms of the agreement, Synageva shareholders would receive $115.00 in cash and 0.6581 shares of Alexion implying a total per share value of $230 calculated on the nine day volume weighted average closing price of Alexion stock till May 5, 2015.
Array BioPharma, Inc. (Array) announced its third quarter 2015 results on May 4, 2015. The Company posted a decline in revenue as it fell $1.2 million from $7.8 million same period last year to $6.6 million. However, the Company reported a net income of $58.3 million, or $0.37 per diluted share, compared to a net loss of $24.9 million, or $0.20 per diluted share, for the same period in fiscal 2014.
Sarepta Therapeutics, Inc. (Sarepta) on May 7, 2015 announced its first quarter March 2015 financial results. Sarepta reported a non-GAAP net loss of $47.4 million, or $1.15 per share, compared to a non-GAAP net loss of $20.7 million for the first quarter of 2014, or $0.55 per share. The Wall Street analysts polled by Thomson had an average projection of a loss of $1.01 per share.
Fate Therapeutics, Inc. announced on May 6, 2015 that it has entered into a strategic research collaboration and license agreement with Juno Therapeutics to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates, thereby improving their therapeutic potential for cancer patients.
Dyax Corp. announced its financial results for the first quarter on April 29, 2015. The Company reported total revenues of $20.4 million, as compared to $14.1 million for the comparable quarter in 2014, representing a growth of 44.7% YoY.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article